Ghost Tree Capital’s Larimar Therapeutics LRMR Stock Holding History

Ghost Tree Capital’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.31M	Buy	+200,000	New	+$1.61M	0.4%	52
2024 Q2	–	Sell	-210,603	Closed	-$1.6M	–	76
2024 Q1	$1.6M	Buy	+210,603	New	+$1.64M	0.44%	60
2022 Q2	–	Sell	-100,000	Closed	-$405K	–	40
2022 Q1	$405K	Sell	100,000 -125,000	-56%	-$818K	0.09%	41
2021 Q4	$2.43M	Buy	225,000 +25,000	+13%	+$278K	0.87%	39
2021 Q3	$2.31M	Buy	200,000 +100,000	+100%	+$1.2M	0.67%	48
2021 Q2	$982K	Buy	+100,000	New	+$1.13M	0.27%	49
2019 Q1	–	Sell	-62,500	Closed	-$3.71M	–	40
2018 Q4	$3.71M	Hold	62,500	–	–	1.35%	25
2018 Q3	$8.77M	Buy	62,500 +53,978	+633%	+$6.55M	1.86%	22
2018 Q2	$1.05M	Buy	+8,522	New	+$724K	0.31%	37
2015 Q4	–	Sell	-5,417	Closed	-$2.08M	–	64
2015 Q3	$2.08M	Buy	+5,417	New	+$2.44M	0.93%	42
2014 Q4	–	Sell	-6,250	Closed	-$1.47M	–	77
2014 Q3	$1.47M	Buy	+6,250	New	+$1.42M	0.8%	48

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ghost Tree Capital's LRMR Position: Q3 2024 in Review

Ghost Tree Capital opened a new position in Larimar Therapeutics (LRMR) in Q3 2024: 200,000 shares worth $1.31M. The stake represents 0.4% of the portfolio and ranks #52 among its holdings. This is a return to the name: Ghost Tree Capital previously reported a position in LRMR as recently as Q1 2024.

Ghost Tree Capital first reported a position in LRMR in Q3 2014 and has held it in 11 quarters since. The position peaked at $8.77M in Q3 2018. 123 funds tracked by Wall St. Rank hold LRMR as of Q3 2024.

Ghost Tree Capital held 200,000 shares of Larimar Therapeutics worth $1.31M as of Q3 2024.
Larimar Therapeutics was a new Ghost Tree Capital position in Q3 2024.
Larimar Therapeutics made up 0.4% of Ghost Tree Capital's portfolio in Q3 2024, its #52 holding.
Ghost Tree Capital first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 11 quarters since.
Ghost Tree Capital's Larimar Therapeutics position peaked at $8.77M in Q3 2018.
123 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.